A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults
Abstract Shigella is a leading cause of moderate to severe diarrhea worldwide and of diarrhea-associated deaths in children under 5 years of age in low-and middle-income countries. A vaccine against shigellosis is in high demand. SF2a-TT15, a synthetic carbohydrate-based conjugate vaccine candidate...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-03-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-023-00624-y |
| _version_ | 1797421437804347392 |
|---|---|
| author | Shiri Meron-Sudai Valeria Asato Amos Adler Anya Bialik Sophy Goren Ortal Ariel-Cohen Arava Reizis Laurence A. Mulard Armelle Phalipon Dani Cohen |
| author_facet | Shiri Meron-Sudai Valeria Asato Amos Adler Anya Bialik Sophy Goren Ortal Ariel-Cohen Arava Reizis Laurence A. Mulard Armelle Phalipon Dani Cohen |
| author_sort | Shiri Meron-Sudai |
| collection | DOAJ |
| description | Abstract Shigella is a leading cause of moderate to severe diarrhea worldwide and of diarrhea-associated deaths in children under 5 years of age in low-and middle-income countries. A vaccine against shigellosis is in high demand. SF2a-TT15, a synthetic carbohydrate-based conjugate vaccine candidate against Shigella flexneri 2a (SF2a) was found safe and strongly immunogenic in adult volunteers. Here, SF2a-TT15 at 10 µg oligosaccharide (OS) vaccine dose is shown to induce a sustained immune response in magnitude and functionality in the majority of volunteers followed up 2 and 3 years post-vaccination. High levels of either one of the humoral parameters as well as the number of specific-IgG memory B-cells determined 3 months after vaccination were good predictors of the durability of the immune response. This study is the first to examine the long-term durability of antibody functionality and memory B-cell response induced by a Shigella vaccine candidate. |
| first_indexed | 2024-03-09T07:17:20Z |
| format | Article |
| id | doaj.art-063fa043e27d4d6bbd83224197fa1938 |
| institution | Directory Open Access Journal |
| issn | 2059-0105 |
| language | English |
| last_indexed | 2024-03-09T07:17:20Z |
| publishDate | 2023-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj.art-063fa043e27d4d6bbd83224197fa19382023-12-03T08:19:57ZengNature Portfolionpj Vaccines2059-01052023-03-018111010.1038/s41541-023-00624-yA Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adultsShiri Meron-Sudai0Valeria Asato1Amos Adler2Anya Bialik3Sophy Goren4Ortal Ariel-Cohen5Arava Reizis6Laurence A. Mulard7Armelle Phalipon8Dani Cohen9School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Ramat AvivSchool of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Ramat AvivSchool of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Ramat AvivSchool of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Ramat AvivSchool of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Ramat AvivSchool of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Ramat AvivSchool of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Ramat AvivInstitut Pasteur, Université Paris Cité, CNRS UMR3523, Unité de Chimie des BiomoléculesInstitut Pasteur, Innovation Lab. VaccinesSchool of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Ramat AvivAbstract Shigella is a leading cause of moderate to severe diarrhea worldwide and of diarrhea-associated deaths in children under 5 years of age in low-and middle-income countries. A vaccine against shigellosis is in high demand. SF2a-TT15, a synthetic carbohydrate-based conjugate vaccine candidate against Shigella flexneri 2a (SF2a) was found safe and strongly immunogenic in adult volunteers. Here, SF2a-TT15 at 10 µg oligosaccharide (OS) vaccine dose is shown to induce a sustained immune response in magnitude and functionality in the majority of volunteers followed up 2 and 3 years post-vaccination. High levels of either one of the humoral parameters as well as the number of specific-IgG memory B-cells determined 3 months after vaccination were good predictors of the durability of the immune response. This study is the first to examine the long-term durability of antibody functionality and memory B-cell response induced by a Shigella vaccine candidate.https://doi.org/10.1038/s41541-023-00624-y |
| spellingShingle | Shiri Meron-Sudai Valeria Asato Amos Adler Anya Bialik Sophy Goren Ortal Ariel-Cohen Arava Reizis Laurence A. Mulard Armelle Phalipon Dani Cohen A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults npj Vaccines |
| title | A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults |
| title_full | A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults |
| title_fullStr | A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults |
| title_full_unstemmed | A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults |
| title_short | A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults |
| title_sort | shigella flexneri 2a synthetic glycan based vaccine induces a long lasting immune response in adults |
| url | https://doi.org/10.1038/s41541-023-00624-y |
| work_keys_str_mv | AT shirimeronsudai ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT valeriaasato ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT amosadler ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT anyabialik ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT sophygoren ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT ortalarielcohen ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT aravareizis ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT laurenceamulard ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT armellephalipon ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT danicohen ashigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT shirimeronsudai shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT valeriaasato shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT amosadler shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT anyabialik shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT sophygoren shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT ortalarielcohen shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT aravareizis shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT laurenceamulard shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT armellephalipon shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults AT danicohen shigellaflexneri2asyntheticglycanbasedvaccineinducesalonglastingimmuneresponseinadults |